en Tranylcypromine trifluoperazine

Tranylcypromine/trifluoperaizne
Combination of
Tranylcypromine	Monoamine oxidase inhibitor
Trifluoperazine	Typical antipsychotic
Clinical data
Trade names	Parstelin, Parmodalin, Jatrosom N, Stelapar
Routes of; administration	Oral
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
CAS Number	60108-71-6;

Tranylcypromine/trifluoperazine (brand names Parstelin, Parmodalin, Jatrosom N, Stelapar) is a combination formulation of the monoamine oxidase inhibitor antidepressant drug tranylcypromine and the typical antipsychotic drug trifluoperazine that has been used in the treatment of major depressive disorder.^[1]^[2]^[3] It contains 10 mg tranylcypromine and 1 mg trifluoperazine.^[3]^[4] The drug has been in clinical use since at least 1961.^[3]

It may come to assume a certain place in the treatment of borderline personality disorder.^[5]

References

^ Dart RC (2004). "Monoamine Oxidase Inhibitors". Medical Toxicology. Lippincott Williams & Wilkins. pp. 825–. ISBN 978-0-7817-2845-4.
^ Stahl SM (15 May 2014). Prescriber's Guide: Stahl's Essential Psychopharmacology. Cambridge University Press. pp. 783–. ISBN 978-1-107-67502-5.
^ ^a ^b ^c Straker M, Grauer H (July 1961). "Clinical Study of a Potent Antidepressant, Tranylcypromine with Trifluorperazine (Parstelin ), in the Aged Chronically Ill". Canadian Medical Association Journal. 85 (3): 127–130. PMC 1848140. PMID 20326829.
^ Kalinowsky LB, Hippius H, Klein HE (1982). Biological Treatments in Psychiatry. Grune and Stratton, Harcourt Brace Jovanovich. ISBN 978-0-8089-1423-5.
^ Cowdry, R. W., & Gardner, D. L. (1988). Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Archives of general psychiatry, 45(2), 111–119. https://doi.org/10.1001/archpsyc.1988.01800260015002

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.